Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Adds 119 New Drugs to NRDL after 51% Price Cuts

publication date: Dec 28, 2020

China has added 119 new therapies to its National Reimbursement Drug List after drugmakers from China and the rest of the world accepted price reductions of 51% to be included. Although the price cuts were painful, they were 10% less severe than last year. The negotiations took longer than expected. The additions to the NRDL include three PD-1 inhibitors from China biopharmas, bringing the total to four. PD-1 products from BeiGene, Jiangsu Hengrui Medicine and Shanghai Junshi Biosciences join an Innovent PD-1 checkpoint inhibitor, the first China-developed offering in the category. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China